5 THINGS YOU NEED TO KNOW ABOUT

TYPE 2 INFLAMMATORY DISEASES

WHAT IS TYPE 2 INFLAMMATION?

Recent scientific developments have shown that excessive type 2 inflammation, an overactive immune system response, underlies different atopic, allergic and inflammatory diseases.[1-3]



WHAT ARE THE SYMPTOMS OF TYPE 2 INFLAMMATION?

Signs and symptoms vary by disease. For instance, type 2 inflammation can contribute to **the debilitating itch of atopic dermatitis**,[4] **unpredictable and sometimes life-threatening asthma attacks**,[5,6] and **the loss of smell and taste** associated with **chronic rhinosinusitis** with **nasal polyps**.[7, 8]

WHAT FACTORS PLAY A ROLE IN TYPE 2 INFLAMMATION?

Genetic, environmental, and other physiological factors play a role in the presence of type 2 inflammation. The genetics of type 2 inflammation may explain why some people experience more than one of these conditions throughout the course of their life, and why these conditions can run in families.

CAN PEOPLE HAVE MORE THAN ONE TYPE 2 INFLAMMATORY DISEASES?

It is not uncommon for people to have two or more type 2 inflammatory diseases, with different levels of severity. When a person has multiple coexisting type 2 inflammatory diseases, management is even more challenging.

Up to 35% of people with asthma also have AD and up to 50% of those with AD have asthma[11,12]

About 17% of people with CRSwNP also have AD and around 13% of those with AD have CRSwNP[14,15]

Around 50% of people with CRSwNP also have asthma and up to 45% of those with severe asthma have CRSwNP[13,16-20]

WHAT IS THE BURDEN OF DISEASE ASSOCIATED WITH TYPE 2 INFLAMMATORY DISEASES?

Type 2 inflammatory diseases can affect both physical and mental health, with the severity of disease burden increasing when diseases are coexisting. People with inadequately controlled, moderate-to-severe type 2 inflammatory diseases commonly experience frequent and debilitating sleep disturbances and mental health issues.[4,6,9,10, 15-23]

About 46% of adolescents with AD have their school life negatively impacted by AD flares[4]

Up to 50% of people with severe asthma report symptoms of depression[15]

More than 90% of people with CRSwNP report sleep quality loss[14]

1 - N. A. Gandhi, B. L. Bennett and N. M. Graham, "Targeting key proximal drivers of type 2 inflammation in disease," Nature Reviews Drug Discovery, vol. 15, no. 1, pp. 35-50, 16 October 2016. **2** - S. Carr, E. Chan, and W. Watson, "Eosinophilic esophagitis," Allergy, Asthma & Clinical Immunology, vol. 14, no. Suppl 1, p. 58, 2018. **3** - J. W. Steinke and J. M. Wilson, "Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances.," Journal of Asthma and Allergy, vol. 9, pp. 37-43, 2016. **4** - T. Zuberbier , S. Orlow and A. Paller, "Patient perspectives on the management of atopic dermatitis," Journal of Allergy and Clinical Immunology, vol. 118, no. 1, pp. 226-232, 2006. **5** - Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2018. Available at: http://ginasthma.org/download/832/. Last accessed April 2018. **6** - Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009. **7** - Kato A et al. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015; Apr, 64(2):121-30. **8** - Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507-12. **9** - P. Marcus, R. Arnold and S. Ekins, "A retrospective randomized study of asthma control in the US: results of the CHARIOT study," Current Medical Research and Opinion, vol. 24, no. 12, pp. 3443-3452, 2008. **10** - E. Ponte, R. Franco and H. Nascimento, "Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis," Allergy, vol. 63, no. 5, pp. 564-569, 2008. polyps and asthma: clinical and radiological features, allergy and inflammation markers," Medicina, vol. 44, no. 4, pp. 257-265, 2008. **11** - C. Philpott, S. Erskine and C. Hopkins, "Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study," Respiratory Research, vol. 19, p. 129, 2018. **12** - H. Won, Y. Kim and M. Kang, "Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset," Ann Allergy Asthma Immunol, vol. 120, no. 4, pp. 389-394, 2018. **13** - E. Simpson, E. Guttman-Yassky and D. Margolis, "Chronicity, comorbidity, and life course impairment in atopic dermatitis: Insights from a cross-sectional study in US adults.," in 25th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, 2016. **14** - L. Rudmik and Z. Soler, "Medical Therapies for Adult Chronic Sinusitis: A Systematic Review," JAMA Dermatology, vol. 314, no. 9, pp. 926-939, 2015. **15** - C. Rand, R. Wright and M. Cabana, "Mediators of asthma outcomes," J Allergy Clin Immunol, vol. 129, no. 301, pp. 136-141, 2012. **16** - D. Stull, L. Roberts and L. Frank, "Relationship of nasal congestion with sleep, mood, and productivity," Current Medical Research and Opinion, vol. 23, no. 4, pp. 811-819, 2007. **17** - S. Nordic, E. Blomgvist and P. Olsson , "Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma," Acta Oto-Laryngologica, vol. 131, no. 8, pp. 826-832, 2011. **18** - M. Iskedjian, C. Piwko and N. Shear, "Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence," Am J Clin Dermatol, vol. 5, no. 4, pp. 267-279, 2004. **19** - J. Cury Martins, C. Martins and V. Aoki, "Topical tacrolimus for atopic dermatitis (Review)," The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd., 2016. **20** - S. Meggitt, J. Gray and N. Reynolds, "Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial," Lancet, vol. 367, no. 9513, pp. 839-846, 2006. **21** - D. Ashcroft, P. Dimmock and R. Garside, "Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials," BMJ, vol. 330, no. 7490, pp. 516-522, 2005. **22** - M. Schram, E. Roekevisch and M. Leeflang, "A randomized trial of methotrexate versus azathioprine for severe atopic eczema," J Allergy Clin Immunol, vol. 128, no. 2, pp. 353- 359, 2011. **23** - Philpott, C. Hopkins and S. Erskine, "The burden of revision sinonasal surgery in the UK - data from the Chronic Rhinosinusitis Epidemiology Study (CRES): a cross-sectional study.," BMJ Open, vol. 5, p. e006680, 2015.

IMM.19.09.0003 | Approved September 2019

SANOFI